The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity

Cell Reports

Volumn 20, Issue 7, 2017, Pages 1692-1704

  Xie, Yangchun ^a,b,c   Zhu, Shan ^a   Song, Xinxin ^c   Sun, Xiaofang ^a   Fan, Yong ^a   Liu, Jinbao ^a   Zhong, Meizuo ^b   Yuan, Hua ^d   Zhang, Lin ^e   Billiar, Timothy R ^c   Lotze, Michael T ^c   Zeh, Herbert J ^c   Kang, Rui ^c   Kroemer, Guido ^{f,g,h,i,j,k,l}   Tang, Daolin ^a,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d JILIN UNIVERSITY   (China)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h INSERM   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

ACSL4; ddp4; ferroptosis; iron; lipid peroxidation; NOX; NRF2; precision medicine; SLC7A11; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV; ERASTIN; ONCOPROTEIN; PROTEIN P53; SLC7A11C PROTEIN; UNCLASSIFIED DRUG; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; IRON; NITRILE; PIPERAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SMALL INTERFERING RNA; VILDAGLIPTIN;

ARTICLE; BIOACCUMULATION; CANCER PROGNOSIS; CELL DEATH; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; FERROPTOSIS; GENE FUNCTION; GENE LOSS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID PEROXIDATION; MOLECULAR INTERACTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CACO-2 CELL LINE; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL TUMOR; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL NEOPLASMS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; LIPID PEROXIDATION; MICE; MICE, NUDE; NITRILES; PIPERAZINES; PYRROLIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027880924     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.07.055     Document Type: Article

References (57)

1. Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M.L., Schreiber, S., Schäfer, H., Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32 (2013), 4825–4835.
2. Bieging, K.T., Mello, S.S., Attardi, L.D., Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14 (2014), 359–370.
3. Chen, X.W., He, Z.X., Zhou, Z.W., Yang, T., Zhang, X., Yang, Y.X., Duan, W., Zhou, S.F., Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 42 (2015), 999–1024.
4. Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., Der, C.J., Drugging the undruggable RAS: Mission possible?. Nat. Rev. Drug Discov. 13 (2014), 828–851.
5. Deacon, C.F., Lebovitz, H.E., Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes. Metab. 18 (2016), 333–347.
6. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
7. Dixon, S.J., Patel, D.N., Welsch, M., Skouta, R., Lee, E.D., Hayano, M., Thomas, A.G., Gleason, C.E., Tatonetti, N.P., Slusher, B.S., Stockwell, B.R., Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife, 3, 2014, e02523.
8. Doll, S., Proneth, B., Tyurina, Y.Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13 (2017), 91–98.
9. Dolma, S., Lessnick, S.L., Hahn, W.C., Stockwell, B.R., Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3 (2003), 285–296.
10. Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 (2015), 517–532.
11. Fadini, G.P., Avogaro, A., Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul. Pharmacol. 55 (2011), 10–16.
12. Fearon, E.R., Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6 (2011), 479–507.
13. Friedman, A.A., Letai, A., Fisher, D.E., Flaherty, K.T., Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15 (2015), 747–756.
14. Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16 (2014), 1180–1191.
15. Green, D.R., Kroemer, G., Cytoplasmic functions of the tumour suppressor p53. Nature 458 (2009), 1127–1130.
16. Havre, P.A., Abe, M., Urasaki, Y., Ohnuma, K., Morimoto, C., Dang, N.H., The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 13 (2008), 1634–1645.
17. Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12 (2016), 1425–1428.
18. Huerta, S., Goulet, E.J., Livingston, E.H., Colon cancer and apoptosis. Am. J. Surg. 191 (2006), 517–526.
19. Humpton, T.J., Vousden, K.H., Regulation of cellular metabolism and hypoxia by p53. Cold Spring Harb. Perspect. Med., 6, 2016, a026146.
20. Jackson, E.K., Context-dependent effects of dipeptidyl peptidase 4 inhibitors. Curr. Opin. Nephrol. Hypertens. 26 (2017), 83–90.
21. Jennis, M., Kung, C.P., Basu, S., Budina-Kolomets, A., Leu, J.I., Khaku, S., Scott, J.P., Cai, K.Q., Campbell, M.R., Porter, D.K., et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 30 (2016), 918–930.
22. Jiang, L., Kon, N., Li, T., Wang, S.J., Su, T., Hibshoosh, H., Baer, R., Gu, W., Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (2015), 57–62.
23. Kagan, V.E., Mao, G., Qu, F., Angeli, J.P., Doll, S., Croix, C.S., Dar, H.H., Liu, B., Tyurin, V.A., Ritov, V.B., et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13 (2017), 81–90.
24. Khoo, K.H., Verma, C.S., Lane, D.P., Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13 (2014), 217–236.
25. Lam, C.S., Cheung, A.H., Wong, S.K., Wan, T.M., Ng, L., Chow, A.K., Cheng, N.S., Pak, R.C., Li, H.S., Man, J.H., et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS ONE, 9, 2014, e98582.
26. Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., Gu, W., Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149 (2012), 1269–1283.
27. Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S.R., Dewitz, C., De Zen, F., Prokai, A., Zuchtriegel, G., Krombach, F., Welz, P.S., et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA 111 (2014), 16836–16841.
28. Liu, L., Omar, B., Marchetti, P., Ahrén, B., Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. Biochem. Biophys. Res. Commun. 453 (2014), 398–404.
29. Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J.C., Maziere, J.C., Chauffert, B., Galmiche, A., Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 133 (2013), 1732–1742.
30. Louandre, C., Marcq, I., Bouhlal, H., Lachaier, E., Godin, C., Saidak, Z., François, C., Chatelain, D., Debuysscher, V., Barbare, J.C., et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 356:2 Pt B (2015), 971–977.
31. Masaki, H., Okano, Y., Ochiai, Y., Obayashi, K., Akamatsu, H., Sakurai, H., alpha-tocopherol increases the intracellular glutathione level in HaCaT keratinocytes. Free Radic. Res. 36 (2002), 705–709.
32. Matsushita, M., Freigang, S., Schneider, C., Conrad, M., Bornkamm, G.W., Kopf, M., T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 212 (2015), 555–568.
33. Muller, P.A., Vousden, K.H., p53 mutations in cancer. Nat. Cell Biol. 15 (2013), 2–8.
34. Ou, Y., Wang, S.J., Li, D., Chu, B., Gu, W., Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl. Acad. Sci. USA 113 (2016), E6806–E6812.
35. Pang, R., Law, W.L., Chu, A.C., Poon, J.T., Lam, C.S., Chow, A.K., Ng, L., Cheung, L.W., Lan, X.R., Lan, H.Y., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6 (2010), 603–615.
36. Parrales, A., Iwakuma, T., p53 as a regulator of lipid metabolism in cancer. Int. J. Mol. Sci., 17, 2016, E2074.
37. Puzio-Kuter, A.M., The role of p53 in metabolic regulation. Genes Cancer 2 (2011), 385–391.
38. Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A., Zhang, D.D., Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA 108 (2011), 1433–1438.
39. Schott, C., Graab, U., Cuvelier, N., Hahn, H., Fulda, S., Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. Front. Oncol., 5, 2015, 131.
40. Shimada, K., Skouta, R., Kaplan, A., Yang, W.S., Hayano, M., Dixon, S.J., Brown, L.M., Valenzuela, C.A., Wolpaw, A.J., Stockwell, B.R., Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12 (2016), 497–503.
41. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., Linkermann, A., Stockwell, B.R., Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136 (2014), 4551–4556.
42. Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., Tang, D., Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64 (2016), 488–500.
43. Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., Tang, D., Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63 (2016), 173–184.
44. Tanaka, T., Camerini, D., Seed, B., Torimoto, Y., Dang, N.H., Kameoka, J., Dahlberg, H.N., Schlossman, S.F., Morimoto, C., Cloning and functional expression of the T cell activation antigen CD26. J. Immunol. 149 (1992), 481–486.
45. Thomasova, D., Bruns, H.A., Kretschmer, V., Ebrahim, M., Romoli, S., Liapis, H., Kotb, A.M., Endlich, N., Anders, H.J., Murine double minute-2 prevents p53-overactivation-related cell death (podoptosis) of podocytes. J. Am. Soc. Nephrol. 26 (2015), 1513–1523.
46. Turk, B., Stoka, V., Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett. 581 (2007), 2761–2767.
47. Vousden, K.H., Ryan, K.M., p53 and metabolism. Nat. Rev. Cancer 9 (2009), 691–700.
48. Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med., 8, 2016, 334ra351.
49. Wang, S.J., Li, D., Ou, Y., Jiang, L., Chen, Y., Zhao, Y., Gu, W., Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17 (2016), 366–373.
50. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23 (2016), 369–379.
51. Yamada, K., Hayashi, M., Madokoro, H., Nishida, H., Du, W., Ohnuma, K., Sakamoto, M., Morimoto, C., Yamada, T., Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS ONE, 8, 2013, e62304.
52. Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26 (2016), 165–176.
53. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
54. Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M.T., Zeh, H.J., Kang, R., Tang, D., The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell. Oncol., 2, 2015, e1054549.
55. Yuan, H., Li, X., Zhang, X., Kang, R., Tang, D., Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478 (2016), 1338–1343.
56. Zhong, J., Rao, X., Rajagopalan, S., An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 226 (2013), 305–314.
57. Zhu, S., Zhang, Q., Sun, X., Zeh, H.J. 3rd, Lotze, M.T., Kang, R., Tang, D., HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res. 77 (2017), 2064–2077.